his.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Cytoplasmic Relocalization of TAR DNA-Binding Protein 43 Is Not Sufficient to Reproduce Cellular Pathologies Associated with ALS In vitro
AstraZeneca-Tufts Laboratory for Basic and Translational Neuroscience, Tufts University School of Medicine, Boston, United States.
IMED Biotech Unit, AstraZeneca Neuroscience IMED, AstraZeneca, Cambridge, United States.
AstraZeneca-Tufts Laboratory for Basic and Translational Neuroscience, Tufts University School of Medicine, Boston, United States.
AstraZeneca-Tufts Laboratory for Basic and Translational Neuroscience, Department of Neuroscience, Tufts University School of Medicine, Boston, MA, USA / IMED Biotech Unit, AstraZeneca Discovery Science, Mölndal, Sweden. (Bioinformatics, Bioinformatik)ORCID-id: 0000-0003-2899-3801
Vise andre og tillknytning
2017 (engelsk)Inngår i: Frontiers in Molecular Neuroscience, ISSN 1662-5099, Vol. 10, artikkel-id 46Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Mutations in the gene TARDBP, which encodes TAR DNA-binding protein 43 (TDP-43), are a rare cause of familial forms of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). While the majority of mutations are found in the C-terminal glycine-rich domain, an alanine to valine amino acid change at position 90 (A90V) in the bipartite nuclear localization signal (NLS) of TDP-43 has been described. This sequence variant has previously been shown to cause cytoplasmic mislocalization of TDP-43 and decrease protein solubility, leading to the formation of insoluble aggregates. Since the A90V mutation has been described both in patients as well as healthy controls, its pathogenic potential in ALS and FTD remains unclear. Here we compare properties of overexpressed A90V to the highly pathogenic M337V mutation. Though both mutations drive mislocalization of the protein to the cytoplasm to the same extent, M337V produces more significant damage in terms of protein solubility, levels of pathogenic phosphorylation, and formation of C-terminal truncated protein species. Furthermore, the M337V, but not the A90V mutant, leads to a downregulation of histone deacetylase 6 and Ras GTPase-activating protein-binding protein. We conclude that in the absence of another genetic or environmental 'hit' the A90V variant is not sufficient to cause the deleterious phenotypes associated with ALS and FTD, despite prominent cytoplasmic protein relocalization of TDP-43.

sted, utgiver, år, opplag, sider
2017. Vol. 10, artikkel-id 46
Emneord [en]
TAR DNA-binding protein 43 (TDP-43), amyotrophic lateral sclerosis (ALS), frontotemporal dementia, mutation, neurodegenerative diseases, protein misfolding disease
HSV kategori
Identifikatorer
URN: urn:nbn:se:his:diva-14041DOI: 10.3389/fnmol.2017.00046ISI: 000394648800002PubMedID: 28286471Scopus ID: 2-s2.0-85014051932OAI: oai:DiVA.org:his-14041DiVA, id: diva2:1136078
Tilgjengelig fra: 2017-08-25 Laget: 2017-08-25 Sist oppdatert: 2018-11-23bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMedScopus

Personposter BETA

Delsing, Louise

Søk i DiVA

Av forfatter/redaktør
Delsing, Louise
I samme tidsskrift
Frontiers in Molecular Neuroscience

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 164 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf